Taro Announces Completion of $250 Million Share Repurchase Program

HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it recently completed its $250 million share repurchase program. The company bought back 1,801,099 of its ordinary shares in open market transactions at an average price of $138.80 per share. The repurchase program was announced by the company on March 15, 2016, and was completed on August 18, 2016.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160819005714/en/

Taro Pharmaceutical Industries Ltd.
William J. Coote, 914-345-9001
[email protected]

Source: Taro Pharmaceutical Industries Ltd.

You May Also Be Interested In

• Cleantek Industries Secures Sale of HALO SE Units for Deployment in Alaska
• Patients Representing the Power of Advanced Therapies to Take Center Stage at Emily Whitehead Foundation's 2026 Believe Ball
• PETER PIPER PIZZA UNVEILS $1 MILLION INVESTMENT IN NEW GAMES, LIMITED-TIME BITES FOR THE ULTIMATE FAMILY NIGHT OUT